Overview

Furoscix in Heart Failure Patients With Diuretic Resistance

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
0
Participant gender:
All
Summary
This will be a randomized, open-label pilot study of 60 patients with and without diuretic resistance who were recently admitted and discharged for acute decompensated heart failure with and oral furosemide regimen testing whether Furoscix is more effective at achieving post-discharge outpatient diuresis than standard of care. Diuretic resistance will be identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF hospitalization, and atrial Fibrillation) score which has been integrated into the electronic health record. The score is integer-based with a score of > 11 indicating diuretic resistance with high likelihood of poor outcomes. The primary outcome is spot urine sodium at 1 hour, 4 hours, and 8 hours post-treatment.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
scPharmaceuticals, Inc.
Treatments:
Furosemide
Criteria
Inclusion Criteria:

- English speaking patients discharged after ward hospitalization for acute
decompensated heart failure with admission NT-proBNP >1000

- Able to be screened and enrolled within 24-72 of discharge

- Recent echocardiogram (6 months or less)

- Discharged with home furosemide dose and able to bring prescription to research visit

Exclusion Criteria:

- Chronic kidney disease stage 5 (GFR<15) or End Stage Kidney Disease

- Systolic blood pressure <100

- ICU hospitalization within 3 months

- Inotrope use within last 3 months

- Home inotropes

- Electrolyte abnormalities on discharge

- Inadequate data for BAN-ADHF score

- Pregnant

- Prior heart transplantation or left ventricular assist device

- Low-output heart failure

- Concurrent use of non-loop diuretic

- Advanced liver disease

- Severe malnutrition

- Skin/Soft tissue condition precluding Furoscix

- Inability to collect urine